Isolator gloves serve as the final critical barrier in Grade A aseptic processing areas to separate operators and prevent microbial contamination. Following the official implementation of the 2022 revision of EU GMP Annex 1, control of glove integrity has transitioned from optional practice to a mandatory audit requirement for pharmaceutical manufacturers facing domestic and international GMP inspections.
Visual inspection by operators alone can no longer meet regulatory requirements. Tiny pinholes may easily lead to product contamination, batch rejection and major non-conformities raised during audits. Based on the official text of EU GMP, this article elaborates on the optimal compliance solution for glove leak testing in sterile facilities from five dimensions: regulatory requirements, testing technologies, one-stop supporting solutions, data compliance and intelligent analysis.
Key Requirements for Glove Integrity Derived from EU GMP Annex 1 Clause 4.21
According to the original text of Clause 4.21 in EU GMP Annex 1, mandatory control requirements for isolators and Restricted Access Barrier Systems (RABS) are clearly defined, which are also frequently inspected during audits:
4.21 The materials used for glove systems (for both isolators and RABS), should be demonstrated to have appropriate mechanical and chemical resistance. The frequency of glove replacement should be defined within the Contamination Control Strategy (CCS).
Isolators: a. For isolators, leak testing of the glove system should be performed using a methodology demonstrated to be suitable for the task and criticality. The testing should be performed at defined intervals. Generally glove integrity testing should be performed at a minimum frequency of the beginning and end of each batch or campaign. Additional glove integrity testing may be necessary depending on the validated campaign length. Glove integrity monitoring should include a visual inspection associated with each use and following any manipulation that may affect the integrity of the system. For manual aseptic processing activities where single unit or small batch sizes are produced, the frequency of integrity verification may be based on other criteria, such as the beginning and end of each manufacturing session. b. Integrity /leak testing of isolator systems should be performed at defined intervals.
RABS: For RABS, gloves used in the Grade A area should be sterilised before installation and sterilised or effectively bio-decontaminated by a validated method prior to each manufacturing campaign. If exposed to the background environment during operation, disinfection using an approved methodology following each exposure should be completed. Gloves should be visually examined with each use, and integrity testing should be performed at periodic intervals.
Six Core Requirements for Glove Integrity
1.Testing methods shall be validated Glove leak testing shall adopt validated methods matching process risks. Visual inspection can act as supplementary monitoring, but shall not replace quantitative instrumental integrity testing. The rationale is straightforward: human eyes cannot identify micro pinholes effectively.
2.Testing frequency shall be defined and incorporated into the Contamination Control Strategy (CCS) For isolator gloves, integrity testing shall be carried out at predefined intervals. Test points shall be established based on production cycles, usage conditions and risk assessment. Additional intermediate testing shall be considered for long-duration continuous production. Testing frequency, glove replacement intervals and deviation handling workflows shall be documented within the Contamination Control Strategy (CCS), rather than relying merely on site experience or operational routines.
3.Differentiated control requirements apply to isolators and RABS
a. Isolators: Perform scheduled integrity testing; supplementary visual inspections shall be conducted after any operations that may damage gloves.
b. RABS: Conduct visual inspections prior to each use, and implement instrumental integrity testing periodically. Given the distinct operational scenarios and risk profiles of the two barrier systems, identical management protocols shall not be directly adopted.
4.Validation evidence shall support glove material selection and replacement cycles
Validation data shall be available to demonstrate the mechanical strength and chemical disinfection resistance of glove materials. Replacement intervals shall be determined based on material properties, actual service conditions and risk assessment. There exists no universal fixed replacement interval. The key is that manufacturers shall provide justified rationale for the adopted interval.
5.Dual monitoring throughout the lifecycle
Regulations mandate combined control: quantitative instrumental leak testing plus routine visual inspection. A single control measure cannot establish a closed compliance loop.
6.Complete and traceable test data
Relevant test records, raw data and operational logs shall be retained in full compliance with the data integrity principles specified in EU GMP Annex 1.
